— September 15, 2026 · Whole Grains in 87 Trials: Modest Gains Across Heart Risk Factors, Largest at About 4–6 Servings a Day

Table of Contents

1. At a Glance
2. What Counts as a Whole Grain
3. What Was Done
4. What Was Found, Number by Number
5. Where the 4–6 Servings Figure Comes From
6. How It Works
7. How It Fits With Earlier Research
8. What It Cannot Show and What Remains Unknown
9. What the Authors, the Editorial and Others Said
10. Sources and Primary Documents
11. Key Research Papers
12. Connections

At a Glance

• Paper — Naghshi S, Kiani S, Ostadrahimi A, Jayedi A, Mobasseri M, Arefhosseini S, Tutunchi H, Aune D. “Whole-grain consumption and cardiometabolic risk: a meta-analysis of randomized trials.” European Heart Journal, published online September 15, 2026 (ahead of print).
• Design — systematic review and meta-analysis of randomised controlled trials in adults, lasting at least 2 weeks, comparing a diet higher in whole grains with a low-whole-grain, usual or refined-grain diet. Searches ran to November 1, 2024.
• Size — 87 trials. The press release puts the total at “more than 6,500 participants,” and the accompanying editorial at 6,529, from trials in Asia, Europe, the United States, Canada, Australia and Brazil.
• Length — median follow-up of 8 weeks.
• Main result (per 48 g a day, dry weight) — total cholesterol −0.10 mmol/L, LDL cholesterol −0.07 mmol/L, body weight −0.20 kg, waist −0.22 cm, systolic blood pressure −0.82 mmHg, fasting glucose −0.03 mmol/L.
• Dose — largest effects for most outcomes at about 60–100 g a day dry weight, which the authors equate to 115–190 g of food as eaten, or 4–6 servings a day.
• Not measured — heart attacks, strokes and deaths. The trials measured risk factors only.
• Funding — Tabriz University of Medical Sciences (grant 75326), according to the PubMed and Crossref records.

Back to Table of Contents

What Counts as a Whole Grain

The paper used a simple botanical test: “a grain was deemed whole if it contained all three parts of the original kernel, including bran, germ, and endosperm.” The bran is the outer layer, the germ is the part of the seed that sprouts, and the endosperm is the starchy interior. White flour and polished white rice are made mostly from the endosperm: refining mills away the bran and germ, and with them cereal fibre (see wheat bran and fibre).

The editorial gives a fuller version. Whole grains, its authors write, “refer to cereal grains where the three main parts—bran, germ, and endosperm—are all retained in the same proportions as in the intact kernel, whether consumed as whole kernels, flakes, or milled into flour and used in bread and other foods.” Under that definition rolled oats, barley grains, brown rice, whole-wheat flour and rye flour all count, as long as nothing has been taken away.

Food labels are a separate question. A 2017 proposal from the Healthgrain Forum, a not-for-profit group of academics and food-industry members, suggested that a product be labelled “whole grain” only if whole-grain ingredients make up at least 30% of it and outweigh the refined-grain ingredients, both by dry weight. The proposal is guidance, not law. The editorial adds a caution that applies to packaged foods: “When whole-grain ingredients are incorporated into complex industrial formulations with a disrupted grain structure and/or cosmetic additives, such products may also fall into the ultra-processed category” (see ultra-processed foods).

One more detail matters for reading the numbers. The meta-analysis counted whole grain by its dry weight, the weight of the grain itself before cooking or baking, so that porridge, bread and rice could be compared on the same scale. The authors give the conversion themselves: 48 g a day of dry whole grain is “equivalent to ∼90 g or 3 servings of fresh weight,” meaning the food as eaten.

Back to Table of Contents

What Was Done

The team searched PubMed, Scopus, Web of Science, the Cochrane CENTRAL register of trials and Google Scholar up to November 1, 2024. A trial qualified if it randomised adults aged 18 or older, in parallel groups or in a crossover design where each person tries both diets, to more whole grain or to a low-whole-grain, usual or refined-grain diet for at least 2 weeks. It also had to measure at least one of: blood sugar control, blood fats, body size, blood pressure, markers of inflammation, quality of life or side effects. The search found 87 trials described in 101 publications.

The results were combined in two ways:

• Pairwise — the higher-whole-grain diet against its control in each trial, whatever the amount.
• Dose–response — how the effect changed with the amount eaten. This was done as a straight-line estimate per 48 g a day, and as a curve that lets the effect level off or change shape at different intakes. The authors used one-stage mixed-effects models, which let trials with different doses feed into a single curve.

Each trial’s risk of bias was rated with the Cochrane RoB 2 tool, and the certainty of each pooled result was graded with the GRADE system, from high to very low. The authors also set a minimally important difference (MID) for each outcome, the smallest change they count as clinically meaningful. In their words, “Point estimates larger than the MID thresholds were considered important, and those smaller than or equal to the MID were considered clinically irrelevant/unimportant.” That judgement is separate from statistical significance: a result can be statistically clear and still fall below the MID.

Back to Table of Contents

What Was Found, Number by Number

Blood fats and glucose are given in millimoles per litre (mmol/L), the unit used by laboratories in most of the world; US laboratories report the same tests in mg/dL (see the lipid panel). Each figure below is a mean difference with its 95% confidence interval, followed by the number of trials (n) where the abstract gives it. A negative number means lower on more whole grain.

Per 48 g a day of whole grain (straight-line dose–response)

Rated high certainty:

• Body weight −0.20 kg (95% CI −0.31 to −0.09; n = 41)
• Waist circumference −0.22 cm (−0.39 to −0.06; n = 27)
• Total cholesterol −0.10 mmol/L (−0.13 to −0.07; n = 54)
• Interleukin-6, an inflammation signal, −0.12 pg/mL (−0.23 to −0.00; n = 12)

Rated moderate certainty:

• LDL cholesterol −0.07 mmol/L (−0.10 to −0.05; n = 52)
• Triglycerides −0.04 mmol/L (−0.06 to −0.02; n = 52)
• Fasting plasma glucose −0.03 mmol/L (−0.06 to −0.00; n = 44)
• Systolic blood pressure −0.82 mmHg (−1.49 to −0.15; n = 32)

In the full text, C-reactive protein, a general marker of inflammation (see hs-CRP), fell by 0.31 mg/L per 48 g a day (−0.52 to −0.10), and the insulin-resistance score HOMA-IR by 0.08 (−0.16 to −0.01). There was no clear change in HDL cholesterol (0.01 mmol/L; −0.01 to 0.02), diastolic blood pressure (−0.41 mmHg; −0.92 to 0.11), the long-term blood-sugar marker HbA1c (−0.03%; −0.05 to 0.00), fasting insulin, body-fat percentage or the inflammation signal TNF-α.

Higher against lower whole grain (pairwise)

• LDL cholesterol −0.13 mmol/L (−0.17 to −0.08), 69 trials, 5,932 participants, moderate certainty. The authors rate this an “important reduction, greater than the MID threshold.”
• Body weight −0.51 kg (−0.72 to −0.30), 60 trials, 4,390 participants, high certainty, which the authors call a “clinically irrelevant” reduction.
• Fasting plasma glucose −0.07 mmol/L (−0.13 to −0.02), 62 trials, 4,728 participants, moderate certainty, also rated clinically irrelevant.
• C-reactive protein −0.38 mg/L (−0.55 to −0.21), 31 trials, low certainty; HOMA-IR −0.24 (−0.39 to −0.09), 30 trials, low certainty.
• HDL cholesterol 0.01 mmol/L (−0.01 to 0.03), 71 trials: no change.
• Side effects: 7 trials with 742 participants reported them; the risk ratio was 1.53 (0.72 to 3.22), low certainty. The interval includes no difference; the details are in the paper’s supplement, which this site did not read.

How much the trials disagreed

Meta-analyses report heterogeneity as I², the share of the variation between trials that is larger than chance alone would produce. It was moderate to high for several outcomes: 57.9% for LDL cholesterol, 69.3% for fasting glucose, 81.9% for HDL cholesterol and 83.1% for C-reactive protein. The authors write that such differences “may be partially attributable to variations in study populations (e.g. high-risk vs general populations).” They report that “no publication bias was identified from the contour-enhanced funnel plots” for any outcome.

Back to Table of Contents

Where the 4–6 Servings Figure Comes From

The figure comes from the curved dose–response analysis. In the abstract’s words, “Non-linear analyses indicated greatest effects at 60-100 g/day for most outcomes, but at higher intakes (up to 180-220 g/day) for a few outcomes.” Some of the points on those curves:

• At 60 g a day: C-reactive protein −0.58 mg/L (−0.86 to −0.30); systolic blood pressure −2.44 mmHg (−4.29 to −0.58).
• At 80 g a day: total cholesterol −0.21 mmol/L (−0.27 to −0.15); LDL cholesterol −0.16 mmol/L (−0.22 to −0.10); triglycerides −0.08 mmol/L (−0.13 to −0.04).
• At 220 g a day: HDL cholesterol, which showed no change in the straight-line analysis, rose by 0.19 mmol/L (0.05 to 0.34).

In the Discussion the authors translate the range into food: the greatest reductions for most risk factors were “around 60–100 g/day whole-grain intake,” which is “equivalent to an average of 115–190 g fresh weight or 4–6 servings daily of whole grains.” Their conclusion keeps the uncertainty in view: “the certainty of evidence varied across outcomes, and sparse data at higher intake levels limit firm conclusions regarding dose thresholds.”

Three points shape how the range reads. First, few trials tested large amounts. The authors write that this produced “wider CIs at the very high range of intakes (>140 g/day) than at medium levels,” and that “This imprecision reflects the limited number of trials that tested high doses, rather than evidence of no effect.” Second, for body size the curve never reached a level the authors rate as meaningful: “For adiposity measures, changes in effect estimates remained clinically irrelevant and unimportant across the full spectrum of daily whole grain intake.” Third, long-term cohort studies, which follow what people eat over years, found lower risk continuing up to “210–225 g/day of whole-grain foods (∼112–120 g/day dry weight),” a higher figure than the trials’ 60–100 g. The authors name this difference themselves.

The editorial reports that “Current US dietary guidelines recommend 2–4 servings of whole grains per day within an overall pattern that emphasizes ‘real food’,” and its authors read the trial evidence as indicating “that higher whole-grain intakes than presently recommended in some guidelines may be optimal for cardiometabolic health.” The site’s report on the 2025–2030 US Dietary Guidelines covers that document.

Back to Table of Contents

How It Works

The paper does not test mechanisms. Its opening line is that “underlying mechanisms remain unclear,” and the editorial agrees that “our understanding of which specific components and pathways matter most remains incomplete.” Earlier research points to several pathways, each with its own evidence.

• Cereal fibre. The editorial goes back more than half a century: “Sir Denis Burkitt and colleagues proposed that the refining of staple carbohydrates, with the accompanying removal of cereal fiber (i.e. from whole to refined grains), underpinned a broad spectrum of ‘Western’ diseases via effects on stool bulk, transit time, and the colonic milieu.” The site covers dietary fibre in depth.
• Beta-glucan in oats and barley. This soluble fibre has its own trial record. A 2014 meta-analysis of 28 randomised trials found that 3 g or more a day of oat beta-glucan lowered LDL cholesterol by 0.25 mmol/L and total cholesterol by 0.30 mmol/L, with no change in HDL or triglycerides. A 2010 meta-analysis of 11 trials of barley and barley beta-glucan found reductions of 0.27 mmol/L in LDL and 0.30 mmol/L in total cholesterol (see oats, beta-glucan and cholesterol, and how LDL reaches the artery wall).
• Eating less overall. In a 2019 Danish crossover trial of 60 adults at risk of metabolic syndrome, each spending 8 weeks on a whole-grain diet and 8 weeks on a refined-grain diet, body weight fell on the whole-grain diet, “consistent with a reduction in energy intake.” Interleukin-6 and C-reactive protein also fell. Blood-sugar control did not change significantly, there were no major changes in the gut microbiome, and the drop in interleukin-6 was linked with the amount of whole grain eaten, “in particular with intake of rye.”
• Many small changes at once. The lead investigator’s summary in the press release was that “whole grains may benefit cardiovascular health through several modest improvements acting together, rather than through one large effect on a single risk factor.”

The editorial notes “signs of differential effects” by grain, “with oats showing particular effects on blood lipids, rye showing effects on body weight, and brown rice revealing effects in relation to blood lipids and inflammation.” The paper itself is more cautious about comparisons between groups of trials: “Using the ICEMAN tool, the credibility of the observed subgroup effects was rated as low.”

Back to Table of Contents

How It Fits With Earlier Research

Cohort studies. A 2016 dose–response meta-analysis in the BMJ, whose first author is also the senior author of the new paper, pooled 45 prospective studies. Per 90 g a day of whole-grain food (three servings), the relative risk was 0.81 (0.75 to 0.87) for coronary heart disease, 0.78 (0.73 to 0.85) for cardiovascular disease, 0.88 (0.75 to 1.03) for stroke, 0.83 (0.77 to 0.90) for death from all causes and 0.85 (0.80 to 0.91) for death from cancer. Lower risk continued up to 210–225 g a day for most outcomes. There was “little evidence of an association with refined grains, white rice, total rice, or total grains.” Studies of this kind show associations in people who chose their own diets, and cannot on their own show cause and effect.

The 2019 carbohydrate-quality review. A series of reviews in The Lancet, partly funded by the World Health Organization, combined 185 prospective studies and 58 clinical trials. Risk reductions were greatest when daily fibre intake was between 25 g and 29 g, and “Similar findings for whole grain intake were observed.” The certainty of the evidence was graded moderate for dietary fibre and low to moderate for whole grains.

Earlier trial reviews. These found less. A 2017 Cochrane review accepted only trials of 12 weeks or more and found nine, with 1,414 participants. None reported heart attacks, strokes or deaths, none lasted longer than 16 weeks, and total cholesterol did not differ (0.07 mmol/L; −0.07 to 0.21; low-quality evidence). Its authors concluded there was “insufficient evidence from RCTs.” A 2015 meta-analysis of 24 trials in healthy adults found LDL cholesterol 0.09 mmol/L lower (−0.15 to −0.03) and total cholesterol 0.12 mmol/L lower, with oats having the largest effect on total cholesterol and no effect on HDL; study duration was associated with the changes in total and LDL cholesterol. The new paper sums up this history: “two meta-analyses of RCTs found no significant effect of increased whole-grain intake on body weight measures, while another meta-analysis only found small effects on blood lipids.” The authors attribute their clearer result to “substantially more trials,” several outcomes analysed together, and dose–response models that allowed for differences in dose.

Brown and white rice. A 2010 analysis of three US cohorts (39,765 men and 157,463 women) linked white rice at 5 or more servings a week with a higher risk of type 2 diabetes (relative risk 1.17; 1.02 to 1.36), and brown rice at 2 or more servings a week with a lower risk (0.89; 0.81 to 0.97). The authors estimated that replacing 50 g a day of cooked white rice with brown rice was associated with a 16% lower risk (see brown rice, whole grains and diabetes).

The editorial sets the new paper against this background: it “complements the large body of observational data by showing that at least part of the association between whole-grain intake and lower cardiometabolic risk is likely to be causal.”

Back to Table of Contents

What It Cannot Show and What Remains Unknown

• Risk factors, not events. No trial in the analysis counted heart attacks, strokes or deaths. The lead investigator said in the press release that “the included trials did not assess cardiovascular events directly, so longer-term studies are needed to confirm this.”
• Short trials. The authors write that “the median duration of follow-up was 8 weeks, which may be insufficient to observe larger effects.” Whether the changes persist, grow or fade over years is not known from these trials.
• Small effects. The editorial is direct: “the effects observed are small.” Its authors expect a larger effect over time and from several markers changing together, which they describe as “possibly” leading to clinically relevant effects. By the paper’s own thresholds, the LDL result counts as important, while body-weight and fasting-glucose changes do not.
• High intakes. Few trials tested more than 140 g a day, so the curves are uncertain there.
• Mixed trials. Heterogeneity was moderate to high for several outcomes, comparisons between groups of trials were rated low credibility, and the diastolic blood pressure, HbA1c, interleukin-6 and body-fat results were “not robust and sensitive to the influence of single studies.”
• Which grain, in which form. According to the editorial, the meta-analysis “does not allow the relative contributions of different grains, food structures, or processing levels to be disentangled.” Whether intact grains, flakes and flour act alike, and where whole-grain ultra-processed products fit, remain open questions.
• Side effects. Only 7 trials reported them, and the evidence was rated low certainty.
• What this site did not read. The table of trial characteristics, the risk-of-bias counts, the results for individual grain types and the supplementary files were not available to this site. Nothing here is stated about them beyond what the abstract, the parts of the full text that were readable and the editorial say.

The editorial calls for trials and cohorts that “more systematically integrate omics technologies (metabolomics, microbiomics, and proteomics)” to explain how whole grains act. Long trials that count cardiovascular events have not yet been done.

Back to Table of Contents

What the Authors, the Editorial and Others Said

The lead investigator. Helda Tutunchi of Tabriz University of Medical Sciences, quoted in the European Society of Cardiology’s press release:

• “Although higher whole-grain intake has long been linked to better heart health in population studies, clinical trials have produced mixed findings.”
• “This is the largest and most comprehensive meta-analysis of randomized controlled trials on wholegrain intake and cardiovascular risk factors.”
• “However, most of the trials we included were relatively short, with an average duration of about eight weeks. As a result, we cannot determine whether these benefits are maintained over the long term.”
• “We found that most benefits occur at intakes of approximately 60 to 100 grams per day, toward the upper end of current dietary recommendations. These findings do not necessarily call for major changes to existing guidelines, but they support public health strategies that help people increase their whole-grain intake and move toward the higher end of current targets.”

The editorial. Cecilie Kyrø, Anne Tjønneland and Anja Olsen of the Danish Cancer Institute in Copenhagen, who declare no conflict of interest, wrote that “intakes of 60–100 g/day dry weight (∼4–6 servings) were found to be clearly related to relevant cardiometabolic improvements.” Their closing line is about food policy: “the challenge is to make minimally processed whole-grain staples accessible, affordable, and culturally acceptable, while avoiding a drift towards ultra-processed products that merely add whole grains to otherwise highly processed formulations.”

The press release. The European Society of Cardiology’s release of September 16 was headlined “Four to six servings of wholegrain per day lowers risk factors for heart disease,” and one of its key takeaways read: “Results show that eating four to six servings per day brings major health benefits.” The word “major” is the release’s. The paper reports modest changes and rates several of them below its own threshold for clinical importance. The release also says benefits were “already apparent” at 30 to 40 g a day; this site did not find that figure in the parts of the paper it could read.

Since then (September 30, 2026)

On September 30, 2026, the American College of Cardiology published a scientific statement on nutrition and heart disease. Its press release that day said: “Current evidence supports replacing saturated fats with unsaturated fats, particularly from sources like liquid plant oils, nuts, seeds and fish, and prioritizing whole grains and other high-fiber food.” The site’s report is ACC Nutrition Statement: Diet Quality Over Single Nutrients.

Back to Table of Contents

Sources and Primary Documents

Every figure attributed to the meta-analysis above was taken from its PubMed abstract or from its open-access full text (Creative Commons CC BY 4.0), not from the press release. Bibliographic details were checked against the PubMed and Crossref records.

1. Naghshi S, Kiani S, Ostadrahimi A, Jayedi A, Mobasseri M, Arefhosseini S, Tutunchi H, Aune D (2026). Whole-grain consumption and cardiometabolic risk: a meta-analysis of randomized trials. European Heart Journal, published online September 15, 2026, ehag519. — doi:10.1093/eurheartj/ehag519 · PubMed PMID: 42743912
2. Kyrø C, Tjønneland A, Olsen A (2026). Whole grains and cardiometabolic health: strong evidence, new questions in an ultra-processed world. European Heart Journal, published online September 15, 2026, ehag724 (editorial). — doi:10.1093/eurheartj/ehag724 · PubMed PMID: 42743911
3. European Society of Cardiology (September 16, 2026). Four to six servings of wholegrain per day lowers risk factors for heart disease (press release). — escardio.org
4. ScienceDaily (September 16, 2026). Scientists find the whole grain “sweet spot” for better heart health (the press release, with the editorial quoted). — sciencedaily.com
5. American College of Cardiology (September 30, 2026). Overall Diet Quality Key to Heart Health (press release). — acc.org

Back to Table of Contents

Key Research Papers

Background papers cited above. Each entry was checked against its PubMed record and its Crossref DOI record before it was written down.

1. Aune D, Keum N, Giovannucci E, Fadnes LT, Boffetta P, Greenwood DC, et al. (2016). Whole grain consumption and risk of cardiovascular disease, cancer, and all cause and cause specific mortality: systematic review and dose-response meta-analysis of prospective studies. BMJ 353:i2716. — PubMed PMID: 27301975
2. Reynolds A, Mann J, Cummings J, Winter N, Mete E, Te Morenga L (2019). Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. The Lancet 393(10170):434-445. — PubMed PMID: 30638909
3. Kelly SA, Hartley L, Loveman E, Colquitt JL, Jones HM, Al-Khudairy L, et al. (2017). Whole grain cereals for the primary or secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews 8:CD005051. — PubMed PMID: 28836672
4. Hollænder PL, Ross AB, Kristensen M (2015). Whole-grain and blood lipid changes in apparently healthy adults: a systematic review and meta-analysis of randomized controlled studies. American Journal of Clinical Nutrition 102(3):556-572. — PubMed PMID: 26269373
5. Whitehead A, Beck EJ, Tosh S, Wolever TM (2014). Cholesterol-lowering effects of oat β-glucan: a meta-analysis of randomized controlled trials. American Journal of Clinical Nutrition 100(6):1413-1421. — PubMed PMID: 25411276
6. AbuMweis SS, Jew S, Ames NP (2010). β-glucan from barley and its lipid-lowering capacity: a meta-analysis of randomized, controlled trials. European Journal of Clinical Nutrition 64(12):1472-1480. — PubMed PMID: 20924392
7. Roager HM, Vogt JK, Kristensen M, Hansen LBS, Ibrügger S, Mærkedahl RB, et al. (2019). Whole grain-rich diet reduces body weight and systemic low-grade inflammation without inducing major changes of the gut microbiome: a randomised cross-over trial. Gut 68(1):83-93. — PubMed PMID: 29097438
8. Sun Q, Spiegelman D, van Dam RM, Holmes MD, Malik VS, Willett WC, Hu FB (2010). White rice, brown rice, and risk of type 2 diabetes in US men and women. Archives of Internal Medicine 170(11):961-969. — PubMed PMID: 20548009
9. Ross AB, van der Kamp JW, King R, Lê KA, Mejborn H, Seal CJ, Thielecke F; Healthgrain Forum (2017). Perspective: A Definition for Whole-Grain Food Products-Recommendations from the Healthgrain Forum. Advances in Nutrition 8(4):525-531. — PubMed PMID: 28710140

PubMed Topic Searches

1. PubMed: Whole grains and cardiometabolic risk in randomised trials
2. PubMed: Whole-grain dose–response and cardiovascular mortality
3. PubMed: Oat and barley beta-glucan and LDL cholesterol
4. PubMed: Whole grains, C-reactive protein and interleukin-6
5. PubMed: Brown rice, white rice and type 2 diabetes

Back to Table of Contents

Connections

• News Archive
• Grains and Staples — the site’s grain section
• Whole Grain vs Refined Wheat — heart disease and diabetes research
• Oats — the grain with the strongest cholesterol record
• Oats, Beta-Glucan and Cholesterol — the soluble-fibre trials
• Barley — beta-glucan for cholesterol and blood sugar
• Brown Rice — the whole form of rice
• Brown Rice and Type 2 Diabetes — the cohort evidence
• Wheat — whole wheat, bran and germ
• Quinoa — the Andean seed eaten like a grain
• Dietary Fiber — types of fibre and what they do
• Cholesterol Management — LDL, HDL and triglycerides
• Coronary Artery Disease — the disease these risk factors predict
• Hypertension — high blood pressure
• Type 2 Diabetes — blood sugar and insulin resistance
• Lipid Panel — the cholesterol and triglyceride test
• hs-CRP — the inflammation marker measured in the trials
• Ultra-Processed Foods — the editorial’s concern about whole-grain products
• ACC Nutrition Statement — the September 30, 2026 cardiology statement

Back to Table of Contents